Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation. - Wikidata - wikimedia - TriplyDB

Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation.

Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation.

http://www.wikidata.org/entity/Q39987593

about

International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands Integrating the puzzle pieces: the current atomistic picture of phospholipid-G protein coupled receptor interactions LPA is a chemorepellent for B16 melanoma cells: action through the cAMP-elevating LPA5 receptor Molecular characterization of oxysterol binding to the Epstein-Barr virus-induced gene 2 (GPR183)Biosynthesis of alkyl lysophosphatidic acid by diacylglycerol kinases.International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂ Autotaxin: structure-function and signaling Role of platelets in neuroinflammation: a wide-angle perspective New members of the mammalian glycerophosphodiester phosphodiesterase family: GDE4 and GDE7 produce lysophosphatidic acid by lysophospholipase D activity Targeted deletion of LPA5 identifies novel roles for lysophosphatidic acid signaling in development of neuropathic pain Characterization of non-olfactory GPCRs in human sperm with a focus on GPR18 Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors.International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature.Lysophosphatidic Acid Is Associated with Atherosclerotic Plaque Instability by Regulating NF-κB Dependent Matrix Metalloproteinase-9 Expression via LPA2 in Macrophages.Type 2 scavenger receptor CD36 in platelet activation: the role of hyperlipemia and oxidative stress.LPA receptor signaling: pharmacology, physiology, and pathophysiology.Lysophospholipid receptor nomenclature review: IUPHAR Review 8.Lysophosphatidic acid receptor 5 inhibits B cell antigen receptor signaling and antibody response Lysophosphatidic acid in atherosclerotic diseases Lysophosphatidic acid-activated Cl- current activity in human systemic sclerosis skin fibroblasts A GPR18-based signalling system regulates IOP in murine eye.Aiming drug discovery at lysophosphatidic acid targets.N-arachidonyl-glycine modulates synaptic transmission in superficial dorsal horn Protection of neuroblastoma Neuro2A cells from hypoxia-induced apoptosis by cyclic phosphatidic acid (cPA).Synthesis and pharmacological evaluation of the stereoisomers of 3-carba cyclic-phosphatidic acid GPR92/LPA₅ lysophosphatidate receptor mediates megakaryocytic cell shape change induced by human atherosclerotic plaques Autotaxin and LPA1 and LPA5 receptors exert disparate functions in tumor cells versus the host tissue microenvironment in melanoma invasion and metastasis Combined mitigation of the gastrointestinal and hematopoietic acute radiation syndromes by an LPA2 receptor-specific nonlipid agonist.Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors.Uncovering unique roles of LPA receptors in the tumor microenvironment.Insights into the pharmacological relevance of lysophospholipid receptors.Lys39-Lysophosphatidate Carbonyl Oxygen Interaction Locks LPA1 N-terminal Cap to the Orthosteric Site and partners Arg124 During Receptor Activation So what do we call GPR18 now?Virtual screening for LPA2-specific agonists identifies a nonlipid compound with antiapoptotic actions.Benzyl and naphthalene methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic activity.Lysophosphatidic acid-induced arterial wall remodeling: requirement of PPARgamma but not LPA1 or LPA2 GPCR.N-acyl amino acids and N-acyl neurotransmitter conjugates: neuromodulators and probes for new drug targets.Lysophosphatidic acid-1-receptor targeting agents for fibrosis.Endogenous metabolites as ligands for G protein-coupled receptors modulating risk factors for metabolic and cardiovascular disease.Comparative analyses of lysophosphatidic acid receptor-mediated signaling.

P2860

Q24605072-9EE02460-0CB3-4653-A817-5BF9BEADD561 Q26828893-3378B6F5-47C6-4360-8B93-B3863920A198 Q27310850-73894D25-E41E-4E0A-9D72-700C94AE62AC Q28115398-49A84F45-84E9-4D87-BB41-450CFE08F1E2 Q28118835-E4BE0D57-430E-40F3-8892-CAF9835F1F25 Q28298445-8639CFE8-239F-49A2-9A21-8E3F64617CB4 Q28307790-17692F1E-A6BA-4C87-81F6-3EDEF17EF67D Q28393808-991D9D9B-158F-4B97-BDB9-468F4D54F1F4 Q28509679-53F19198-3B3F-4714-9986-6292D8FDE516 Q28585279-6845D4DC-39D7-4258-9943-935B51292828 Q28828513-56E54F08-9E24-4F27-844B-81D7745B017C Q30410634-1158B0AE-376A-46F5-983B-E70510DEE81D Q30429523-C5512481-9874-46CF-B7EC-F5C05B93CE02 Q33607215-4CFE456C-EC46-4ECA-9547-F17B45817DB3 Q33641499-78559EFB-26D5-42ED-8009-58DC548336C5 Q33825153-95BF8CBC-5DEA-4C35-94BD-0AAA8508DE26 Q34025135-73076D2C-44CE-45E5-964A-D557241A312C Q34025718-C972D795-FC34-43C9-9134-4858BBB6E370 Q34273486-D2BD731C-BD4E-4BCA-86C2-35B1C6AF78F3 Q34310766-2FACC97B-CDB7-4394-871C-716888CEDAF4 Q34331021-8E94A93C-D10F-460E-A30B-D7C526949454 Q34339759-AA31D764-3FBC-4CDC-9C13-9F73D1CFB817 Q34356128-6E52D8AF-B75F-461C-ACCC-09886332580C Q34516098-E5C0DBFC-6BF9-40CB-B9D9-AD90FFB88CCB Q34580111-4D44B90C-C48D-41B8-881A-08B38F4727D6 Q34682812-2BC7552D-F77F-4425-8447-789DF1C13F5D Q34980426-28E78A5B-FA9F-48C8-ADB8-6E25231C1253 Q35108170-479758D0-75A2-496A-9698-8036099019F2 Q35551835-FD09507C-D4F1-4CA4-811B-F08EE556A96B Q35628694-1BBCE976-2A43-46A1-B475-332899DEDEF8 Q35853199-88FBA4A9-DEE4-4BAB-BBD6-C158D189E8A2 Q35974518-9524EEFA-47B5-4FFF-958F-8EDE41B6D2CE Q36176460-D80696DD-E186-4EFA-8888-E0D146AC342B Q36412800-EAE063DC-2D09-4575-9398-7714D920D05F Q36452780-114C160B-D5E3-40F8-B970-FE55637C4A0A Q37384489-7D268140-7698-450F-BEC0-991D68B8E14F Q37774694-F32C8C2B-CC7A-4A46-B6A8-8CF04853E2D7 Q37857284-F6A0EACD-3B63-4FCB-A420-1E95672509EF Q38067511-E2A44B59-6BBB-4FDA-A4EB-FCB8D8D5DD69 Q38366897-EFE319F2-5049-418B-8BC2-7FAF646AA2B3

P2860

Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation.

http://www.wikidata.org/entity/Q39987593

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Unique ligand selectivity of t ...... in human platelet activation.

@en

Unique ligand selectivity of t ...... in human platelet activation.

@nl

type

label

Unique ligand selectivity of t ...... in human platelet activation.

@en

Unique ligand selectivity of t ...... in human platelet activation.

@nl

prefLabel

Unique ligand selectivity of t ...... in human platelet activation.

@en

Unique ligand selectivity of t ...... in human platelet activation.

@nl

P1433

Q39987593-2E4F6B1B-F1DC-459A-9CC3-96BCB29A7D3E

P1476

Q39987593-CB90BB02-202B-4A68-82B9-089DE1CEFB9A

P2093

Q39987593-058F2A12-8E13-48BB-A253-CD779AE748C9

Q39987593-34AD1EEC-9326-49CC-9AE5-1F09BC02B590

Q39987593-53D1288D-74BB-4446-BED9-327DEE388C95

Q39987593-5A136D95-613E-4D3D-8013-76B9FFF7BC5B

Q39987593-64A2CF4B-970A-4B1C-A72D-52761647A750

Q39987593-76EAC89D-E415-4030-94D1-36A9BADEED05

Q39987593-88A13AA4-F6A9-4C66-9F77-48EDF3792796

Q39987593-AD42D280-FE0C-49A6-9CF2-94D81DC7D1A4

Q39987593-FCB734E9-CCEE-4A0E-AB73-B0E68874860E

P2860

Q39987593-045EBB58-6771-41C4-9EF4-8BB430AC4138

Q39987593-0C4BB5CC-F83F-48B0-ABFD-4D3FEC8725B5

Q39987593-0E846A3F-F761-4DEA-881E-1F9D9BB4461C

Q39987593-17D055CA-6533-4A4E-8D42-420E40D73DA1

Q39987593-197192D8-D0E5-44EB-B354-12343C46428C

Q39987593-1E1ABD28-39AB-4E92-B0A8-F1BCC15E258A

Q39987593-23E80621-CF16-47FB-A1D3-A04938B01431

Q39987593-33BFF791-CEC9-4D63-801F-BD6B9474A29B

Q39987593-34F35780-3258-4643-85DB-EB89ECCDC5EB

Q39987593-3F0939A2-57E5-497F-AF10-DB8DEC787979

P304

Q39987593-917BF724-1622-4719-AD71-396FC65470E6

P31

Q39987593-4137B711-0369-4CD1-AFAD-072296DEC872

P356

Q39987593-B4002E97-894A-4535-BA30-481958E08BCB

P407

Q39987593-804F1DB8-57E3-4809-9404-7258F2B37146

P433

Q39987593-9C0E4095-D07C-469F-88A6-E6DAE8DBD12B

P478

Q39987593-0E562EB2-0089-41A8-8DA9-028B0F489F4F

P577

Q39987593-8701B4C0-0541-47B5-91AC-6FC01C0F6807

P698

Q39987593-81B1DD8C-49ED-4AE4-A8D9-3B076B18F9DF

P932

Q39987593-5295C82B-18D6-4543-94B6-6946D0D54DFC

P356

JBC.M109.003194

P1433

Journal of Biological Chemistry

P1476

Unique ligand selectivity of t ...... in human platelet activation.

@en

P2093

Abby L Parrill

http://www.w3.org/2001/XMLSchema#string

Anna L Khandoga

http://www.w3.org/2001/XMLSchema#string

Donna H Perygin

http://www.w3.org/2001/XMLSchema#string

Gabor Tigyi

http://www.w3.org/2001/XMLSchema#string

James I Fells

http://www.w3.org/2001/XMLSchema#string

Jesica R Williams

http://www.w3.org/2001/XMLSchema#string

Pankaj Goyal

http://www.w3.org/2001/XMLSchema#string

Wolfgang Siess

http://www.w3.org/2001/XMLSchema#string

Yuko Fujiwara

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid

G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth

The plaque lipid lysophosphatidic acid stimulates platelet activation and platelet-monocyte aggregate formation in whole blood: involvement of P2Y1 and P2Y12 receptors

The emerging role of lysophosphatidic acid in cancer

Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes

GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5

Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94

Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions

Lysophosphatidic acid is a bioactive mediator in ovarian cancer.

Regulation of anandamide tissue levels by N-arachidonylglycine.

P304

17304-17319

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M109.003194

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

284

http://www.w3.org/2001/XMLSchema#string

P577

2009-04-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19366702

http://www.w3.org/2001/XMLSchema#string

P932

2719366

http://www.w3.org/2001/XMLSchema#string